Skip to main content
THERACRYF PLC logo

THERACRYF PLC — Investor Relations & Filings

Ticker · TCF ISIN · GB00BSVYN304 LEI · 213800NO3E6TSTQO8K20 IL Professional, scientific and technical activities
Open in API
Filings indexed 362 across all filing types
Latest filing 2018-05-14 Investor Presentation
Country GB United Kingdom
Listing IL TCF

About THERACRYF PLC

https://theracryf.com/

TheraCryf PLC is a clinical-stage therapeutics company focused on developing a new generation of innovative medicines for behavioural brain disorders and oncology. The company's research and development efforts are centered on sulforaphane-based compounds. Its primary therapeutic focus is on conditions such as opioid and alcohol abuse, binge eating disorder, anxiety, and fatigue. TheraCryf's business strategy is to generate compelling clinical data for its drug candidates with the goal of partnering its programs with larger pharmaceutical companies for late-stage development and commercialization.

Recent filings

Filing Released Lang Actions
Upcoming Investor Presentations
Investor Presentation Classification · 95% confidence The document is an announcement from Evgen Pharma regarding upcoming investor presentations. It provides details on dates, locations, and registration links for these events. It also mentions that a copy of the investor presentation will be available on their website at a later time. Since this is a short announcement about upcoming events rather than the presentation itself, and it is distributed via the RNS (Regulatory News Service), it falls under the category of a general regulatory announcement.
2018-05-14 English
Grant of further European patent
Investor Presentation Classification · 95% confidence The document is a short announcement (under 5,000 characters) issued via the Regulatory News Service (RNS) regarding the grant of a European patent for Evgen Pharma PLC. It does not fit into specific categories like financial reports, M&A, or director dealings. As it is a general corporate announcement that does not fall into the other specialized categories, it is classified as a Regulatory Filing (RNS).
2018-05-02 English
Second Price Monitoring Extn
Regulatory Filings Classification · 100% confidence The document is a short notification from the London Stock Exchange's Regulatory News Service (RNS) regarding a 'Second Price Monitoring Extension' for Evgen Pharma PLC. It is a technical market announcement regarding trading volatility and auction extensions, which does not fit into specific categories like financial reports, dividends, or director dealings. Therefore, it falls under the general regulatory announcement category.
2018-04-26 English
Price Monitoring Extension
Regulatory Filings Classification · 98% confidence The document is a short notification from the London Stock Exchange's Regulatory News Service (RNS) regarding a 'Price Monitoring Extension' for Evgen Pharma PLC. It is a standard market regulatory announcement concerning trading mechanics rather than a financial report, management update, or corporate action. As it does not fit into specific categories like dividends, share issues, or earnings, it falls under the general regulatory filing category.
2018-04-26 English
Presentation at World Orphan Drug Congress USA
Regulatory Filings Classification · 98% confidence The document is a short announcement (RNS) from Evgen Pharma PLC regarding an upcoming presentation by their CEO at the World Orphan Drug Congress. It does not contain the presentation slides themselves, nor is it a financial report, dividend notice, or regulatory filing of a specific type. As it is a general corporate news announcement that does not fit into the other specific categories, it is classified as a Regulatory Filing (RNS).
2018-04-24 English
Research Collaboration with Imperial College
Regulatory Filings Classification · 98% confidence The document is a press release issued via the London Stock Exchange's RNS (Regulatory News Service) regarding a new research collaboration between Evgen Pharma and Imperial College London. It does not fit into specific categories like financial reports, dividends, or director dealings. As it is a general corporate announcement regarding business operations and research partnerships, it falls under the 'Regulatory Filings' (RNS) category.
2018-03-20 English

Browse filings by year

13 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.